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This study aimed to identify new peptide antigens from Chlamydia ( C .) trachomatis in a proof of concept
approach which could be used to develop an epitope-based serological diagnostic for C . trachomatis related
infertility in women. A bioinformatics analysis was conducted examining several immunodominant proteins
from C. trachomatis to identify predicted immunoglobulin epitopes unique to C . trachomatis . A peptide array
of these epitopes was screened against participant sera. The participants (all female) were categorized into
the following cohorts based on their infection and gynecological history; acute (single treated infection with
C. trachomatis ), multiple (more than one C. trachomatis infection, all treated), sequelae (PID or tubal infertility
with a history of C. trachomatis infection), and infertile (no history of C. trachomatis infection and no detected
tubal damage). The bioinformatics strategy identiﬁed several promising epitopes. Participants who reacted
positively in the peptide 11 ELISA were found to have an increased likelihood of being in the sequelae cohort
compared to the infertile cohort with an odds ratio of 16.3 (95% c.i. 1.65–160), with 95% speciﬁcity and 46%
sensitivity (0.19–0.74). The peptide 11 ELISA has the potential to be further developed as a screening tool for
use during the early IVF work up and provides proof of concept that there may be further peptide antigens
which could be identiﬁed using bioinformatics and screening approaches. 
c © 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
Chlamydia ( C .) trachomatis is the most prevalent sexually transmit-
ted bacterial infection worldwide, with 1,307,893 infections reported
in the USA in 2010 [ 1 ]. The infection is frequently asymptomatic and
thus actual case numbers are higher than those notiﬁed [ 2 , 3 ]. The
major burden of Chlamydia infections relates to the serious seque-
lae, such as pelvic inﬂammatory disease (PID), infertility, and ectopic
pregnancy in women. The nature of the infection and the detection
of the sequelae much later in life mean that it is difﬁcult to predict
the number of untreated infections which progress to serious seque-
lae. A retrospective study of 43,715 women in Sweden over a 10–15
year time frame, using health data repositories, indicated that for the
women who tested positive to C. trachomatis infection; 5.6% had PID,* Corresponding author. Tel.: + 61 7 31386258; fax + 61 7 31386030. 
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Open access under CC BY-NC-ND lic2.7% had ectopic pregnancy, and 6.7% had infertility [ 4 ]. A review
of published studies by Land and co-workers found that diagnosed
lower genital tract infection can progress to PID in 0.43–31% of cases,
to tubal infertility in 0.02–4.6% of cases, and PID progresses to tubal
infertility in 11.4–20% of cases [ 5 ]. 
The pathogenic mechanism, host genetic factors, and other epi-
demiological factors which lead to serious sequelae in a proportion
of infected women are not well understood, although it is clear that
infertility in women is associated with tubal damage resulting in fal-
lopian tube occlusion. Additionally, minor tubal adhesions or damage
to the cilia lining the fallopian tubes are also considered to be C. tra-
chomatis infection related sequelae which impact on fertility. This has
been further supported by a recent ﬁnding by Coppus and co-workers
that participants attending a fertility clinic with high C. trachomatis
serum antibody titers by MIF or ELISA ( > 1:32 or 1.1 respectively) with
patent tubes by hysterosalpingography (HSG) or laparoscopy, had a
33% lower ongoing pregnancy rate [ 6 ]. 
C. trachomatis antibody titers (CAT) are currently the gold standard
for diagnosis of Chlamydia related infertility in women. There are two
main types of tests which most commonly used; immunoﬂuorescenceense.
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(ests (MIF, IF, or WIF) or ELISA. There are several different commer- 
ially available ELISA tests, and they are typically based on major outer 
embrane protein (MOMP) peptides or LPS. The sensitivity and speci- 
city of these tests varies widely between studies for the diagnosis 
f tubal infertility. A recent meta-analysis by Broeze and colleagues 
onﬁrmed this considerable variation even when the same commer- 
ial tests were used between different studies. The ELISA (mainly 
edac, Biomerieux, Labsystems) sensitivity varied from 12% to 69%, 
nd speciﬁcity varied from 62% to 100% [ 7 ]. The immunoﬂuorescence 
ethods were more sensitive (50–91%) but had lower speciﬁcity (35–
5%) [ 7 ]. 
There are also differences in clinical practice regarding the use of 
AT as a routine part of infertility work up. Many clinics prefer to use 
SG or laparoscopy to diagnose tubal infertility in women without 
AT. The guidelines regarding use of CAT in the preliminary infertility 
ork up also vary. The Dutch Society for Obstetrics and Gynecology 
ecommends CAT during initial fertility work up and suggest a ﬁxed 
ut off of IgG MIF 1:32, or ELISA > 1.1, as positive cut off for CAT [ 8 ],
hereas CAT is not mentioned in Australian diagnosis recommenda- 
ions. More accurate CAT implemented during infertility workup has 
he potential to reduce time to successful pregnancy and patient risk 
y indicating deﬁnitive treatment regimes with the goal of removing 
he need for invasive diagnosis by HSG or laparoscopy. 
Despite these differences in clinical acceptance, it remains possi- 
le that new assays targeting different chlamydial antigens could be 
sed to develop more accurate (sensitive and speciﬁc) CATs to pre- 
ict female infertility due to C. trachomatis past infection which could 
e implemented with greater clinical efﬁcacy. This application of a 
ew CAT assay has led to proteomic investigations within the ﬁeld to 
dentify chlamydial antigens for the development of a more sensitive 
nd speciﬁc CAT to predict Chlamydia -related infertility in women. A 
enome wide study using an expression array identiﬁed that a com- 
ination of CT443 (OmcB) and CT381 (ArtJ) had a 67.5% sensitivity 
nd 100% speciﬁcity [ 9 ]. A proteomic approach searching for B and T 
ell antigens recognized by patients with a high MIF titer frequently 
dentiﬁed MOMP, HtrA, OmcB, TART, GroEL, LCR-E, and CT662 [ 10 ]. 
n another study using a western blot strategy on 2-D gels of the 
hlamydia proteome MOMP, PmpD, and OmcB were found to be the 
ost speciﬁc to infection positive participants (not solely infertility) 
 11 ]. HtrA as a full length protein was found to be immunoreactive 
rom C. trachomatis infected participants [ 12 ]. 
In this current study we used a bioinformatics approach to pre- 
ict single antibody epitopes with unique sequence speciﬁcity to C. 
rachomatis from a selected subset of the most frequently identiﬁed 
ntigens from these previously published proteomic investigations. 
 library of peptides based on these epitopes was used in ELISAs with 
atient sera to characterize performance (sensitivity and odds ratio) 
ith 95% speciﬁcity for Chlamydia related sequelae as a proof of con- 
ept for identifying accurate epitopes for Chlamydia related sequelae. 
sing this approach it is possible that additional antigens be identiﬁed 
hat will advance the use of CAT for diagnosis of Chlamydia related 
nfertility in women. 
. Materials and methods 
.1. Bioinformatics analysis to predict peptides with C. trachomatis 
peciﬁcity and putative B cell antigenicity 
C. trachomatis proteins were selected for this study which had pre- 
iously been identiﬁed in multiple studies as highly immunoreactive, 
hen screened against serological positive females with C. trachoma- 
is infection or C. trachomatis- related tubal factor infertility in more 
han one previous investigations. These proteins were: HtrA, cHSP60, 
t443, and Ct381 [ 9 –12 ]. A protein unique to Chlamydia pneumoniae 
Cpn0236) was also included in the study as a negative control [ 13 ]. 
The protein sequences were analysed using a series of in silico bioinformatic analyses to identify potential linear B cell epitopes, and 
the speciﬁcity of these epitopes to C. trachomatis . The sequences of 
the proteins of interest were screened for predicted linear B cell epi- 
topes using BepiPred algorithm software [ 14 ], conﬁrmed with anti- 
genicity prediction software (Kolaskar & Tongaonkar Antigenicity) 
[ 15 ], and hydrophilic domains identiﬁed to avoid transmembrane 
domains (Parker Hydrophilicity Prediction) [ 16 ]. Candidate C. tra- 
chomatis HtrA, cHSP60, CT443, and CT381 linear B cell epitope pep- 
tides were screened for sequence speciﬁcity against the NR database 
where BLAST E values were used as criteria; (1) E values < 0.004 for 
C. trachomatis speciﬁcity, and (2) E values > 0.1 for C. pneumonia e to 
remove nonspeciﬁc epitopes. Regions that did not meet criteria were 
excluded from further study. The predicted epitopes that met crite- 
ria were then used to design a series of 12-mer peptides ( Table 1 ) 
which include partial or complete sequences of these epitopes. Pre- 
dicted peptide epitopes larger than 12 amino acids were split into 
overlapping epitopes. These included epitopes for HtrA (peptides 7–
9; Table 1 ) and HSP60 (peptides 15–18, 23–28, 32–34, and 37–43; 
Table 1 ), two of the most highly reported immunogenic antigens for 
Chlamydia . n = 11) 
2.2. Analysis of epitope array to identify epitopes and development of 
ELISA 
The designed peptide epitopes were commercially synthesized us- 
ing solid phase synthesis onto a Biotin-SGSG motif (Mimotopes, Mel- 
bourne, Australia). All peptides were solubilized in 50% isopropanol 
overnight on a gentle rocker at room temperature. The initial screen- 
ing ELISAs were conducted using the complete peptide epitope array 
against 39 participants that sampled all cohorts. The ELISAs were 
conducted using streptavidin coated plates (Reacti-Bind Streptavidin 
High Binding Capacity Coated 96-well Plates, ThermoScientiﬁc, Aus- 
tralia) where peptides were coated at approximately 0.15 μg / well for 
1 h at room temperature in PBS / 0.1% Tween 20. The plates were then 
washed four times in PBS 0.1% Tween 20, and blocked overnight in 
SuperBlock buffer (Pierce, Australia) with 0.1% Tween 20 at 4 ◦C. The 
participant sera was added to the wells at dilutions of 1 / 200 and 
1 / 1000 (in SuperBlock buffer in PBS with 0.1% Tween 20) and incu- 
bated for 1 h. The plates were washed ﬁve times in 2 × PBS with 0.1% 
Tween 20. The secondary antibody used was goat anti-human IgG- 
HRP (Invitrogen, Australia) at a dilution of 1 / 15,000 in SuperBlock 
buffer PBS with 0.1% Tween 20. The plates were developed by the 
addition of 100 μg / ml 3,3,5,5,-Tetramethyl-benzadine (TMB) (Sigma- 
Aldrich, Australia) in DMSO dissolved in phosphate citrate buffer with 
sodium perborate (Sigma-Aldrich, Australia), incubated for 10 min at 
room temperature and stopped by the addition of 1.0 M H 2 SO 4 . ELISA 
plates were read on a Bio-Rad xMark Microplate Spectrophotometer 
at 450 nm. These ELISAs were conducted by screening the whole array 
against each participant sera with primary and secondary antibody 
only controls on each plate. The peptides that ﬁt criteria for further 
development in the initial analysis were then subjected to further 
analysis. Optimized assays were attempted, which included further 
serological dilution series, and a variety of alteration in washing con- 
ditions. The optimized peptide 11 ELISA was conducted as per the 
above protocol except that 0.2 μg of peptide was coated to each well. 
2.3. Participant / cohort collection and deﬁnitions 
Participants (female) were recruited as a part of the Queensland 
Chlamydia Research Network which includes all Queensland Health 
Sexual Health Clinics, QUT Health Services Medical Centre, and The 
Wesley Reproductive Medicine and Gynecological surgery unit. The 
participants were fully informed and consented prior to participation 
in the study. Ethical approval for the study was obtained via the fol- 
lowing Human Research Ethics Committees: QUT Human Research 
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Table 1 
Results of screening of peptide array against different participant cohorts. For each generated peptide sequence, the predicted epitope is depicted in bold. All peptides have 
been screened bioinformatically for homology with other bacteria. 
# Peptide sequence Mean absorbance at 450 nm (standard deviation) by cohort 
BLAST Sequelae Infertility controls 
Multiple ( n = 
6) Acute ( n = 6) 
C. trach C. pn All ( n = 16) C. pn + ( n = 7) C. pn – ( n = 9) 
HtrA generated peptides (1–14) 
1 SPMLGY SASKKD 0.003 2.4 0.172 (0.059) 0.163 (0.074) 0.145 (0.079) 0.176 (0.071) 0.163 (0.040) 0.169 (0.08) 
2 ADICLAVS SGDQ 0.005 1.2 0.157 (0.057) 0.139 (0.052) 0.123 (0.049) 0.151 (0.052) 0.152 (0.039) 0.169 (0.085) 
3 AVS SGDQEVSQ E 0.01 0.87 0.171 (0.065) 0.154 (0.062) 0.139 (0.069) 0.165 (0.058) 0.175 (0.0369) 0.183 (0.074) 
4 EQQRPQQRDAVR 0.0002 1.7 0.169 (0.061) 0.155 (0.064) 0.140 (0.071) 0.167 (0.059) 0.173 (0.047) 0.164 (0.067) 
5 QKYT AKIVG LDP 0.002 0.006 0.163 (0.060) 0.150 (0.063) 0.126 (0.063) 0.168 (0.060) 0.168 (0.039) 0.176 (0.087) 
6 AISLM MPGTRVI 0.0006 0.12 0.155 (0.058) 0.146 (0.064) 0.126 (0.067) 0.160 (0.062) 0.164 (0.032) 0.163 (0.079) 
7 VT VTQIPTEDGV 0.003 0.036 0.169 (0.073) 0.160 (0.073) 0.134 (0.069) 0.179 (0.072) 0.171 (0.033) 0.165 (0.065) 
8 EDGVSALQKMGV 0.004 0.01 0.153 (0.054) 0.157 (0.058) 0.139 (0.050) 0.171 (0.061) 0.181 (0.050) 0.189 (0.088) 
9 VSALQKMGV RVQ 0.003 0.006 0.176 (0.060) 0.163 (0.069) 0.15 (0.063) 0.173 (0.075) 0.176 (0.060) 0.164 (0.066) 
10 MGVR VQNITGLA 0.36 0.23 0.149 (0.045) 0.141 (0.080) 0.118 (0.053) 0.157 (0.095) 0.143 (0.034) 0.148 (0.069) 
11 ADTRGILVV AVE 0.001 0.11 0.174 (0.062) 0.158 (0.046) 0.16 (0.044) 0.157 (0.049) 0.166 (0.037) 0.199 (0.097) 
12 EAGS PAASAGVA 0.024 0.015 0.156 (0.094) 0.226 (0.053) 0.236 (0.064) 0.216 (0.041) 0.126 (0.046) 0.131 (0.028) 
13 AVNR GRVAS VEE 0.49 0.12 0.159 (0.055) 0.160 (0.075) 0.128 (0.069) 0.184 (0.074) 0.172 (0.044) 0.171 (0.074) 
14 VNR GRVAS VEEL 0.003 0.26 0.165 (0.062) 0.152 (0.072) 0.132 (0.070) 0.166 (0.072) 0.166 (0.036) 0.170 (0.076) 
HSP60 generated peptides (15–48) 
15 YHILSRIELSDP 0.0006 0.87 0.156 (0.058) 0.155 (0.077) 0.126 (0.072) 0.175 (0.076) 0.167 (0.049) 0.172 (0.079) 
16 IELSDPFERIGV 0.001 3.5 0.156 (0.051) 0.149 (0.073) 0.127 (0.078) 0.165 (0.068) 0.172 (0.046) 0.164 (0.067) 
17 FERIGVYFARSL 0.0008 7.1 0.171 (0.055) 0.162 (0.045) 0.153 (0.035) 0.169 (0.052) 0.194 (0.050) 0.194 (0.11) 
18 RSLAKRIHKRHA 0.002 0.32 0.283 (0.014) 0.289 (0.17) 0.243 (0.15) 0.322 (0.18) 0.229 (0.095) 0.244 (0.13) 
19 A DGVISSVILLR 0.01 0.065 0.170 (0.062) 0.144 (0.064) 0.129 (0.069) 0.155 (0.062) 0.146 (0.036) 0.170 (0.073) 
20 LLRA FLKASIPF 0.003 0.44 0.180 (0.060) 0.150 (0.072) 0.133 (0.079) 0.162 (0.068) 0.164 (0.035) 0.171 (0.073) 
21 LKASIPF IDQGL 0.003 0.86 0.161 (0.061) 0.143 (0.079) 0.123 (0.074) 0.158 (0.082) 0.168 (0.033) 0.162 (0.077) 
22 ASIPF IDQGLSP 0.003 0.86 0.155 (0.055) 0.161 (0.089) 0.150 (0.099) 0.170 (0.085) 0.165 (0.031) 0.174 (0.084) 
23 ASALASQKEAVC 0.014 3.5 0.164 (0.052) 0.154 (0.069) 0.137 (0.059) 0.167 (0.075) 0.175 (0.052) 0.173 (0.074) 
24 AYLHSHSFLLKD 0.001 2.4 0.159 (0.051) 0.149 (0.063) 0.130 (0.065) 0.162 (0.061) 0.176 (0.036) 0.170 (0.081) 
25 KDASKVLGLIRS 0.014 2.4 0.164 (0.058) 0.160 (0.070) 0.139 (0.076) 0.176 (0.064) 0.185 (0.045) 0.176 (0.069) 
26 LIRSHLPDPLIG 0.001 1.7 0.164 (0.057) 0.150 (0.082) 0.137 (0.092) 0.160 (0.076) 0.147 (0.034) 0.161 (0.078) 
27 GEAFAEAVAYTG 0.008 0.17 0.176 (0.063) 0.159 (0.082) 0.134 (0.077) 0.177 (0.084) 0.167 (0.038) 0.184 (0.091) 
28 VAYTGHEG A VAL 0.008 5 0.172 (0.075) 0.150 (0.079) 0.123 (0.072) 0.170 (0.081) 0.155 (0.038) 0.181 (0.099) 
29 SQRSG S TLHL FC 0.93 0.62 0.173 (0.059) 0.155 (0.073) 0.132 (0.075) 0.173 (0.070) 0.159 (0.031) 0.180 (0.092) 
30 TLHLKGIQTQKG 0.01 1.2 0.168 (0.063) 0.149 (0.078) 0.128 (0.078) 0.165 (0.079) 0.180 (0.041) 0.171 (0.080) 
31 TQKGYRVP SFFP 0.0006 2.4 0.166 (0.055) 0.158 (0.069) 0.142 (0.043) 0.170 (0.083) 0.176 (0.036) 0.183 (0.082) 
32 FPHDSFHENPIV 0.0006 0.44 0.168 (0.058) 0.152 (0.076) 0.129 (0.065) 0.169 (0.082) 0.180 (0.064) 0.138 (0.079) 
33 NPIVAPKIFVTD 0.0001 1.7 0.157 (0.056) 0.155 (0.069) 0.133 (0.069) 0.173 (0.067) 0.146 (0.076) 0.197 (0.086) 
34 FVTDQKI HCLFP 0.001 1.2 0.16 (0.057) 0.144 (0.064) 0.131 (0.059) 0.154 (0.069) 0.146 (0.038) 0.166 (0.094) 
35 DHAIHN AEDETS 0.001 2.4 0.169 (0.060) 0.156 (0.071) 0.138 (0.076) 0.170 (0.069) 0.178 (0.045) 0.179 (0.072) 
36 ETSRKLLKKRKH 0.003 1.7 0.265 (0.108) 0.252 (0.123) 0.222 (0.083) 0.274 (0.15) 0.195 (0.069) 0.224 (0.105) 
37 RKHR LENSIAII 0.001 0.32 0.155 (0.049) 0.138 (0.055) 0.126 (0.045) 0.146 (0.060) 0.169 (0.047) 0.173 (0.080) 
38 SIAIIPVKQDTA 0.004 1.2 0.152 (0.055) 0.141 (0.053) 0.13 (0.05) 0.149 (0.052) 0.168 (0.040) 0.19 (0.092) 
33 QDTAPLHELALK 0.003 0.87 0.163 (0.051) 0.153 (0.079) 0.133 (0.076) 0.168 (0.081) 0.174 (0.050) 0.191 (0.086) 
40 ALKTLNSTQESG 0.014 0.091 0.170 (0.045) 0.157 (0.075) 0.142 (0.069) 0.167 (0.080) 0.179 (0.055) 0.187 (0.081) 
41 ESGFVLGGGAAL 0.038 0.54 0.178 (0.064) 0.165 (0.069) 0.149 (0.074) 0.176 (0.067) 0.186 (0.03) 0.197 (0.081) 
42 AALLYATQSLSS 0.02 1.7 0.163 (0.062) 0.128 (0.059) 0.110 (0.063) 0.141 (0.055) 0.146 (0.036) 0.179 (0.055) 
43 LSSS PEHSQEEQ 0.003 0.62 0.180 (0.064) 0.160 (0.084) 0.140 (0.079) 0.174 (0.089) 0.165 (0.045) 0.190 (0.097) 
44 EEQAAVQILQTA 0.004 0.048 0.173 (0.062) 0.163 (0.071) 0.143 (0.063) 0.177 (0.076) 0.163 (0.041) 0.224 (0.087) 
45 DKLC SLGT PSLG 0.008 0.026 0.167 (0.058) 0.149 (0.080) 0.121 (0.065) 0.170 (0.087) 0.155 (0.043) 0.189 (0.084) 
46 YGPAYSSS SKDF 0.0005 2.3 0.199 (0.072) 0.237 (0.077) 0.245 (0.032) 0.231 (0.099) 0.202 (0.087) 0.209 (0.052) 
47 VFSSPP FSNKPP 0.0003 0.86 0.208 (0.14) 0.277 (0.097) 0.300 (0.042) 0.250 (0.14) 0.157 (0.043) 0.339 (0.039) 
48 SLSSSPE HSQEE 0.001 0.23 0.116 (0.030) 0.098 (0.022) 0.105 (0.019) 0.093 (0.024) 0.111 (0.038) 0.097 (0.014) 
Ct443 generated peptides (49–51) 
49 VDRKEVAPVHES 0.0005 12 0.107 (0.047) 0.111 (0.045) 0.119 (0.04) 0.106 (0.048) 0.190 (0.24) 0.069 (0.006) 
50 PVSFSGPTKGTIT 0.0005 12 0.193 (0.109) 0.267 (0.13) 0.253 (0.070) 0.276 (0.17) 0.186 (0.093) 0.222 (0.068) 
51 LTVPVSDTENTH 0.0005 0.033 0.140 (0.042) 0.110 (0.036) 0.110 (0.031) 0.109 (0.041) 0.163 (0.079) 0.185 (0.033) 
Ct381 generated peptide (52) 
52 VGIGVASDRPAL 0.001 0.11 0.136 (0.034) 0.108 (0.036) 0.114 (0.029) 0.104 (0.040) 0.164 (0.075) 0.153 (0.057) 
OmpB generated peptide (53) 
53 AVVSSG SDNELA 0.0005 2 0.127 (0.039) 0.130 (0.046) 0.137 (0.026) 0.125 (0.057) 0.178 (0.089) 0.170 (0.063) 
C. pneumoniae Cp0236 generated peptides (54–55) 
54 EHFSPEPPNEPL 0.23 0.00005 0.060 (0.0073) 0.063 (0.072) 0.063 (0.012) 0.063 (0.008) 0.068 (0.011) 0.061 (0.006) 
55 GSSLRTKEGNTI 2.2 0.002 0.057 (0.0052) 0.0099 (0.022) 0.060 (0.006) 0.062 (0.011) 0.059 (0.0076) 0.056 (0.005) 
36 Scott H. Stansﬁeld et al. / Results in Immunology 3 (2013) 33–39 
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ithics Committee approval number 080000268, Prince Charles Hos- 
ital Human Research Ethics Committee approval number EC2809, 
pswich and West Moreton Health Services District Human Research 
thics committee approval number (10-09), Gold Coast Hospital Dis- 
rict Human Research Ethics Committee approval number (200893), 
airns Sexual Health Clinic (HREC / 09 / QCH / 4-554), and The Wesley 
ospital Human Research Ethics Committee (2008 / 02). Clinical data 
as collected from all participants including: age, number of sexual 
artners, fertility status (if known), self reported and patient chart 
eported history of sexually transmitted infections, current and pre- 
ious C. trachomatis infections, contraceptive use and type. Partici- 
ants sourced from the Wesley Reproductive Medicine and Gyneco- 
ogical surgery unit were also asked to allow their gynecologist to 
rovide additional data relating to their infertility status and infertil- 
ty cause. Participants from this clinic were all tested for C. trachomatis 
nfection history using both the MEDAC and Bioclone C. trachomatis 
LISAs (sourced from Bioclone, Sydney, Australia and MEDAC sourced 
rom Biocene, Sydney, Australia). Potentially confounding partici- 
ants were excluded where they were found to be both seropositive 
o C. trachomatis and had a diagnosed cause of infertility that was not 
ubal factor. These participants were excluded due to the potential 
or their infertility to still relate to C. trachomatis immunopathology. 
Participants (female) recruited from the Queensland Chlamydia 
esearch Network were divided into four C. trachomatis cohorts: se- 
uelae, acute, multiple and infertility controls (subdivided by C. pneu- 
oniae serological status). The sequelae cohort included women who 
ad a history of PID, tubal ectopic pregnancy, or tubal factor infertility 
laparoscopy diagnosis) and also a history of C. trachomatis infection 
either by recorded participant medical chart recorded PCR positive 
revious infection, or C. trachomatis positive serology by MEDAC and 
ioclone assays). Acute participants were those who had a history 
f single treated C. trachomatis infection (PCR diagnosis) with no re- 
orted sequelae, and the multiple infections cohort included partici- 
ants who had a history of more than one treated C. trachomatis in- 
ection (PCR diagnosis) with no reported sequelae. These two cohorts 
ere generally recruited at the Sexual Health Clinics. The infertility 
ontrol cohort included women attending the IVF clinic who were in- 
ertile but did not have tubal factor infertility; these participants were 
ll negative for C. trachomatis serology by the MEDAC and Bioclone 
ests. 
Participants (female) were also recruited from patients attending 
he Gynecology outpatient department at the Sarfdarjung Hospital, 
ew Delhi, India. Participants were informed and consented to par- 
icipate in the study. The study was approved by the Sarfdarjung 
ospital Human Research Ethics Committee. Clinical data collected 
ncluded: age, regularity of menstrual cycle, years of infertility (if 
nfertile), clinical details such as cervicitis, bacterial vaginosis, My- 
oplasma sp. culture, Ureaplasma sp. by culture, bacterial vaginosis, 
nd C. trachomatis infection status by direct ﬂuorescence assay and 
CR from swabs. Participants from this study were divided into co- 
orts based on infertility (primary or secondary; any cause), cervicitis 
nd current C. trachomatis genital infection status (assayed by PCR and 
FA). 
. Results 
.1. Screening new peptide antigens using ELISA conﬁrms 
ioinformatic predictions and identiﬁes potential new antigens for 
hlamydia antibody testing 
The peptide array (55 unique peptides) was developed using a 
eries of bioinformatic analyses of the most commonly reported pro- 
eins to have a serological response in C. trachomatis participants. Pro- 
eins previously frequently identiﬁed during screening or proteomic 
tudies when screening with participant sera from C. trachomatis pos- 
tive participants were selected (HtrA, Hsp60, CT443, and CT381), along with a C. pneumoniae speciﬁc protein as a negative control 
(CP0236). MOMP was not included for this study given the existing 
peptide ELISAs based on this protein and the serovar speciﬁc sequence 
variability in this protein. These proteins were then searched bioin- 
formatically for B cell epitopes, as outlined in Section 2 . Predicted 
epitopes were then searched by BLAST to reduce the pool of poten- 
tial epitopes to only those which had high sequence speciﬁcity to C. 
trachomatis . An initial screening assay was conducted to identify pep- 
tides which may be useful detectors of the sequelae disease cohort. 
The peptide array was screened in duplicate against 39 participant 
sera belonging to the four cohorts: sequelae, acute, multiple, and 
infertility controls (subdivided by C. pneumoniae serological status). 
The raw values for each epitope from each participant in each co- 
hort were then analyzed ( Table 1 ). The data was analyzed by ANOVA, 
comparing the data for each cohort to either sequelae or infertility 
control groups. Only peptide 47 showed a signiﬁcant difference ( P < 
0.05, sequelae c.f . acute) when the results were tested for statistical 
signiﬁcance between the cohorts during this initial screening ELISA. 
Speciﬁc criteria for sequelae speciﬁcity was then applied to select 
peptide epitopes for further analysis. 
In order to identify which peptides have the potential for fur- 
ther assay optimization for speciﬁc detection of the sequelae cohort 
a set of criteria were used to select the peptides to develop further. 
The three criteria were: (1) achieve a higher average absorbance in 
the sequelae cohort compared to the combined infertility controls (a 
difference off of > 0.015 was chosen), (2) to avoid false positive detec- 
tion due to prior C. pneumoniae infection ( < 0.015 difference between 
the C. pneumoniae subdivided infertility controls), and (3) distinguish 
sequelae from acute participants ( > 0.015 different in absorbance be- 
tween the two cohorts) ( Table 1 ). These three criteria identiﬁed the 
following four peptides (protein source of the peptide is indicated): 
11 (HtrA: MGVRVQNITGLA), 48 (HSP60: SLSSSPEHSQEE), 51 (Ct443: 
LTVPVSDTENTH), and 52 (Ct381: VGIGVASDRPAL). 
3.2. Peptide 11 ELISA is an effective serological diagnostic for 
chlamydial tubal factor infertility 
In order to optimize the serological assay, performance of the 
different assay conditions trialed with the different sera dilutions 
for each of the four peptides was assessed by area under the curve 
analysis. Speciﬁcity was controlled at ≥95% to establish absorbance 
(450 nm) thresholds reﬂecting a diagnostic use to detect those women 
who have C . trachomatis sequelae from C. trachomatis infection or neg- 
ative cohorts. Peptide 11 showed the most rigorous performance and 
hence only the data from this peptide is shown here. Fig. 1 shows the 
receiver operator characteristic curve for the sera at a 1 / 200 dilution 
comparing participants from sequelae and infertility control cohorts. 
The tested dilution series did not signiﬁcantly change the accuracy 
of the test as there was negligible difference in area under the curve. 
The selection of 1 / 200 dilution was one of practicability, as the ab- 
sorbance threshold was to be 0.184 at a 1 / 800 dilution and 0.296 at 
a 1 / 200 dilution which achieves a better signal to noise threshold for 
assay development. 
The 1 / 200 dilution peptide 11 assay with a 0.296 absorbance 
threshold was found to be able to statistically discriminate partici- 
pants in the sequelae cohort from infertility controls and from acute 
cohorts ( Table 2 ). The comparison of sequelae to infertility controls 
yielded an odds ratio of 16.3 with a 95% conﬁdence interval 1.63–160 
( P = 0.005). The bioinformatic prediction that the test will not be in- 
ﬂuenced by C . pneumoniae serological status was also supported by its 
performance against the infertilty controls, which includes 7 C . pneu- 
moniae seropositive participants. The test was also able to produce a 
positive odds ratio (5.14; 95% conﬁdence interval 1.12–23.5) for se- 
quelae compared to the acute infection cohort, as per the third design 
criteria. The optimised peptide 11 assay was not able to statistically 
discriminate sequelae from the multiple infection cohort at the 0.296 
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Fig. 1. Receiver operator characteristic curve for the sera dilution of 1 / 200 comparing 
participants from sequelae and infertility control cohorts. In the box (bottom right) 
area under the curve (AUC) for 1 / 200, 1 / 400 and 1 / 800 sera dilutions are shown with 
calculated absorbance (450 nm) thresholds for a 95% speciﬁcity cut off. Dashed line 
indicates the 95% speciﬁcity ( x -axis) cut off which corresponds to 46% sensitivity ( y - 
axis). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 absorbance threshold ( P = 0.091), but did yield a positive odds ratio
(4; 95% conﬁdence interval 0.763–21.0) for the comparison. These
results are supportive of the potential utility of such a test during
the initial infertility investigation where women with sequelae are
clearly distinguished from women with a previous acute infection or
women who are negative. 
In order to further analyse if it might be possible to develop a test
to distinguish between women potentially at risk of developing se-
quelae (such as women with multiple exposures) from women who
have had an infection with no evidence of sequelae a different analy-
sis was conducted using a different absorbance cut off. The speciﬁcity
for detecting multiple infections and sequelae from acute could be
further improved by increasing the absorbance threshold to 0.408,
but resulted in a decrease of statistical signiﬁcance from the 0.296
absorbance threshold for the sequelae vs. acute comparison ( P (Abs
= 0.296) = 0.012 to P (Abs = 0.408) = 0.050; Table 2 ). Whilst these
analyses were not statistically signiﬁcant it indicates that this an ap-
proach were the assay may have utility at the GP clinic for women
who wish to determine their future infertility risk could be developed
from this peptide–epitope strategy. 
3.3. Testing the peptide 11 assay as a serological diagnostic using 
cohort of women attending a gynecology clinic in India 
The peptide 11 ELISA was then tested against participants re-
cruited by the Sarfdarjung Hospital Gynaecology Clinic, South Delhi.
The peptide 11 ELISA was tested on 129 participant’s sera attending
the clinic using the optimized 1 / 200 dilution of sera with the de-
signed 95% speciﬁcity absorbance threshold of 0.296. Nine women
tested positive to the peptide 11 ELISA ( Table 3 ) which included 7
women with cervicitis and primary infertility and 2 women with
primary infertility and current C. trachomatis infection. These pro-
portions were signiﬁcantly different to those who tested negative ( P
= 0.039). The women who tested positive in the peptide 11 ELISA
compared to those who tested negative were analyzed for any po-
tential confounders which may have inﬂuenced the result. There was
no statistical signiﬁcance in age of women who tested positive andthose who tested negative ( P = 0.3458, 28.43 average years for pep-
tide 11 positive c.f. 30.16 average years for peptide 11 negative), or
in the patient reported years of infertility ( P = 0.680, 6.47 compared
to 7.11 years for peptide 11 positive group). Furthermore, there were
no signiﬁcant differences in those women who were positive in the
peptide 11 ELISA and whether or not they had current genital infec-
tions ( Mycoplasma , or Ureaplasma ). In comparison, the MEDAC MOMP
ELISA detected 5 women (absorbance above 1.1) including; 2 women
with C. trachomatis and cervicitis, 2 women with primary infertility,
and 1 primary infertility with C. trachomatis infection, who was also
detected by the peptide 11 assay. These proportions were not signiﬁ-
cantly different from those who were negative to the MEDAC MOMP
ELISA ( P = 0.529). 
All of the women who were peptide 11 positive were women with
primary infertility ( Table 3 ). Those women who were positive in the
peptide 11 ELISA had an odds ratio of 8.8 (95% conﬁdence interval 0.5–
156.29) of having primary infertility and not cervicitis or secondary
infertility (irrespective of C. trachomatis status), but the comparison
was not statistically signiﬁcant ( P = 0.075). A positive MEDAC MOMP
ELISA result had a lower odds ratio of 1.82 (95% conﬁdence interval
0.29–11.28) for the same comparison and was also not statistically
signiﬁcant ( P = 0.240). Raw absorbance values for the peptide 11
ELISA did not correlate with MEDAC MOMP ELISA ( R 2 = 0.001, P =
0.677) supporting the independence of these tests and differing rates
of detection. Whilst a large number of the women recruited at this
clinic were positive for a current C. trachomatis infection (47 positive
by both urine DFA and PCR), 2 of the 9 women who tested positive
using the peptide 11 test also had a current infection further sup-
porting that the design of the test does not bias towards detection
women with acute infections in the context of other pathology. Sen-
sitivity and speciﬁcity of peptide 11 or MEDAC performance relative
to the gold standard of laparoscopy or HSG was not possible on these
patients. 
4. Discussion 
This paper reports for the ﬁrst time that a peptide epitope from
C. trachomatis HtrA has the potential to be further developed into
a speciﬁc diagnostic to detect serious sequelae from this infection.
Women who reacted positively in the peptide 11 ELISA developed
during this study had a 16.3 odds ratio of having C. trachomatis se-
quelae (tubal infertility, ectopic pregnancy, or PID) (speciﬁcity 95%
and sensitivity 46%). The test also showed the potential to distin-
guish these women with sequelae from women with a history of C.
trachomatis single treated infection ( P = 0.027, Table 2 ) or multiple
infections ( P = 0.091, Table 2 ), although the cohort numbers were
not large enough in this study to provide statistical validity. This
is an important ﬁnding as very few studies reporting new antigens
for diagnosis of tubal factor infertility report the performance of the
test against infection cohorts (such as acute or multiple infections).
Certainly cohort deﬁnitions in studies such as these are difﬁcult, as
patients may have had previous untreated infections. However, given
that some of the acute and multiple infection participants included
in this study have been sourced at sexual health clinics it is likely
that this cohort includes some participants who may have more in-
fections than diagnosed and yet the assay was still speciﬁc to the
sequelae cohort ( Table 2 ). The poor sensitivity observed in this study
may be improved by future optimization of peptide concentrations
or multiple peptide combination assay formats. Whilst the sensitivity
and technical parameters (absorbance, signal to noise ratio) of the
assay are clearly not adequate for implementation as a diagnostic in
it’s current format, these results support that using bioinformatics
can help to eliminate issues with speciﬁcity (i.e. cross reactivity due
to C. pneumonia sero-positive status), which has been a perceived
barrier to implementation of CAT. This study has been limited to pro-
teins previously identiﬁed as highly immunoreactive for Chlamydia
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Table 2 
Performance of peptide 11 ELISA. 
Comparison 
450 nm Absorbance 
threshold for 
comparison 
Speciﬁcity (95% 
conﬁdence interval) 
Sensitivity (95% 
conﬁdence interval) 
Odds ratio (95% 
conﬁdence interval) 
P value (chi-squared) for 
difference in observed 
proportions 
Sequelae vs. infertily 
controls 
0.296 0.95 (0.75–1.00) 0.46 (0.19–0.74) 16.3 (1.65–160) 0.005 
Multiple vs. infertiliy 
controls 
0.296 0.95 (0.75–1.00) 0.176 (0.038–0.434) 4.07 (0.38–43.4) 0.217 
Acute vs. infertilty 
controls 
0.296 0.95 (0.75–99.9) 0.143 (0.040–0.327) 3.17 (0.33–30.7) 0.299 
Sequelae vs. multiple 0.296 0.82 (0.57–0.96) 0.46 (0.19–0.75) 4 (0.763–21.0) 0.091 
Sequelae vs. acute 0.296 0.86 (0.67–0.96) 0.46 (0.19–0.75) 5.14 (1.12–23.5) 0.027 
Multiple vs. acute 0.296 0.86 (0.67–0.96) 0.18 (0.04–0.43) 1.29 (0.25–5.6) 0.760 
Sequelae vs. acute 0.408 0.96 (0.81–1.00) 0.23 (0.05–0.53) 8.10 (0.75–87.2) 0.050 
Multiple vs. acute 0.408 0.96 (0.82–1.00) 0.06 (0–0.29) 1.68 (0.110–24.6) 0.715 
Table 3 
Comparison of women attending the Sarfdarjung Hospital Gyneacology clinic who were positive in either the peptide 11 or MEDAC MOMP assays by infertility, cervicitis and 
current C. trachomatis infection status. 
Cervicitis Infertility C. trach PCR / DFA status a 
Total number of 
participants Peptide 11 positive MEDAC MOMP positive 
+ − + 3 0 2 
− − − 15 0 0 
− Primary − 25 0 2 
+ Primary − 31 7 0 
− Primary + 35 2 1 
− Secondary − 11 0 0 
− Secondary + 9 0 0 
a C. trachomatis infection status was assessed by positive reactions in both PCR and DFA. Fisher’s exact test for count data shows a signiﬁcant difference in observed cohort 
proportions between peptide 11 positive and negative ( P = 0.039; negative = total – positive). No signiﬁcant difference in observed cohort proportions was demonstrated between 
MEDAC MOMP positive and negative women (Fisher’s exact test for count data; P = 0.529). 
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whus, it provides proof of concept that this strategy, along with fur- 
her assay development (such as assessing assay performance against 
tandard serological tests and improved technical parameters), could 
e successfully implemented to identify new speciﬁc antigens for CAT 
iagnosis of Chlamydia tubal factor infertility. The potential applica- 
ion of this assay during the initial infertility investigation is clearly 
he major focus, hence the need for high speciﬁcity so that few false 
ositives are diagnosed even though with the current low sensitiv- 
ty some true positives will not be diagnosed. However, the analysis 
sing a different absorbance cut off to distinguish between the acute 
nd multiple and acute and sequelae cohorts also supports that with 
urther technical development an assay of this format may also have 
tility at the GP clinic where women may be seeking to examine their 
ertility risks. Therefore, the overall strategy of using a combination of 
revious proteomic data on immunogenic antigens and bioinformatic 
ools to select epitopes for peptide ELISA data was supported by the 
ndings in this study. 
The peptide 11 ELISA in the current format was tested in another 
etting and it was found that 9 out of 129 women attending a gynecol- 
gy clinic in India would be predicted to have tubal infertility using 
his assay. Interestingly, all of these women had primary infertility 
nd none of the women with secondary infertility were positive by 
his assay (no signiﬁcant age difference). The results of the peptide 
1 ELISA and MEDAC MOMP assays were different, however, whilst 
EDAC MOMP titre above 1.1 is recommended in the Dutch fertil- 
ty guidelines as a diagnostic for C. trachomatis sequelae this assay is 
ctually marketed by the manufacturer as test for infection history. 
ence, the different performance of these two assays is not necessar- 
ly unexpected. There were 47 women with a current C. trachomatis 
nfection of the 129 women recruited for this study (36.4%). This 
revalence is slightly higher than a previously reported prevalence 
f C. trachomatis positive women at another clinic in Delhi, however 
here is potential for a recruitment bias in our study as the clinicians 
ere aware that this is a Chlamydia research study (24–30%) (PCR diagnosis) [ 17 ]. C. trachomatis infection prevalence in populations in 
India (generally sexual health clinic, gynecology clinic or sex worker 
screening studies) varies from 7% to 30% [ 18 , 19 ]. It is more difﬁcult 
to estimate the likely percent of infertility that relates to Chlamydia - 
mediated tubal factor infertility. However, we can be guided by two 
different prospective studies where women attending IVF clinics were 
recruited, and the percent of participants with tubal infertility and a 
positive antibody testing for a history of Chlamydia infection calcu- 
lated to be the prevalence of Chlamydia related tubal infertility. In a 
study based in Denmark this prospective screening approach identi- 
ﬁed that that 6.9% of infertile women attending the IVF clinic was due 
to C. trachomatis tubal infertility [ 20 ]. For a similar study conducted 
in China 7.6% of women attending the IVF clinic had C. trachomatis 
tubal infertility [ 21 ]. The participants attending the clinic in India for 
this current investigation do not have access to laparoscopy or HSG 
technologies, meaning it is not possible to validate the results of the 
peptide 11 assay in this second cohort. However, 7.0% of the partic- 
ipants attending the clinic, all with primary infertility, were positive 
by this assay. 
Overall, this study has provided proof of concept that new peptide 
based ELISAs which are highly speciﬁc for detection of women with C. 
trachomatis sequelae such as tubal factor infertility can be developed. 
The assay is under further development to improve the sensitivity 
by including multiple markers within the assay which has shown 
increased sensitivity [ 9 ]. Increased sensitivity may make this assay 
a useful diagnostic for initial fertility work up, and these potential 
improvements may also be useful for implementation as a screening 
tool in epidemiological studies, or within general practice as an early 
warning system for women to plan their families. 
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